The financials
Veracyte, Inc. by the numbers
Veracyte, Inc. (VCYT) reported revenue of $139M in Q1 2026 (quarter ended Mar 31, 2026), up 21% from the same quarter a year earlier. That came with a gross margin of 73% and net income of $29M (21% of revenue). For the full year FY2025, revenue was $517M (+16% year on year) and net income $66M. Its largest product in Jun 2026 was Testing at $146M, 96% of the disclosed total, well ahead of Testing Other at 3.0%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $139M | $114M | +21% |
| Gross profit | $101M | $80M | +27% |
| Operating income | $23M | $2.9M | +680% |
| Net income | $29M | $7.0M | +307% |
| Diluted EPS | $0.35 | $0.09 | +289% |
| Product | Revenue | Share |
|---|---|---|
| Testing | $146M | 96% |
| Testing Other | $4.5M | 3.0% |
| Biopharmaceutical And Other Biopharmaceutical | $802K | 0.5% |
| Biopharmaceutical And Other | $802K | 0.5% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $151.8M (+8.5%)
Testing Other grew +150% year on yearBiopharmaceutical And Other Contract Manufacturing And Testing -100% year on year
Segment Latestquarter on quarteryear on year
- Testing$145.7M$145.7MQoQ +7.8%year on year +19%+7.8%+19%
- Testing Other$4.5M$4.5MQoQ +7.1%year on year +150%+7.1%+150%
- Biopharmaceutical And Other Biopharmaceutical$802.0K$802.0KQoQ +166%year on year -70%+166%-70%
- Biopharmaceutical And Other$802.0K$802.0KQoQ +166%year on year -81%+166%-81%
- Biopharmaceutical And Other Contract Manufacturing And Testing$0.00$0.00QoQ -year on year -100%--100%
Diagnostics & Research
Ranks #14 of 17 by Smart Score